FDA
-
-
-
-
-
-
-
Nuvation Bio to present quality-of-life data for IBTROZI at ASCO 2026
-
-
-
-
-
-
-
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
-
-
-
-
-
-
-
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
-
-
-
-
-
-
-
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Nuvation Bio Inc (NUVB)
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

